How many drugs treat Chancroid?

Drug Landscape tracks 10 marketed treatments for Chancroid (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/chancroid.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Chancroid — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chancroid (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chancroid, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zithromax	azithromycin	Pfizer Inc.	Macrolide antibiotic (azalide)	Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor	1991-11-01
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Minocycline Hydrochloride	MINOCYCLINE	Rempex	Tetracycline-class Drug		1971-01-01
Azo Gantrisin	sulfafurazole	Alra	Sulfonamide Antimicrobial	Endothelin-1 receptor	1971-01-01
Vibramycin	doxycycline	Generic (originally Pfizer)	Tetracycline antibiotic	72 kDa type IV collagenase, Stromelysin-1, Collagenase 3	1967-01-01
Demethylchlortetracycline	DEMECLOCYCLINE	Pfizer	Tetracycline-class Antimicrobial	Estrogen receptor beta	1960-01-01
Minocyclin	Minocyclin	University of Southern California		30S ribosomal protein S4, 30S ribosomal protein S9, Tetracycline resistance protein, class B
Doxycyclin	Doxycyclin	Bulovka Hospital		72 kDa type IV collagenase, Stromelysin-1, Collagenase 3
Meclan	MECLOCYCLINE	Johnson And Johnson	meclocycline

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Chancroid
Alra · 1 drug in Chancroid
Assistance Publique - Hôpitaux de Paris · 1 drug in Chancroid
Bayer AG · 1 drug in Chancroid
Bulovka Hospital · 1 drug in Chancroid
Centre Hospitalier Universitaire Vaudois · 1 drug in Chancroid
Generic (originally Pfizer) · 1 drug in Chancroid
Generic (originally Roche) · 1 drug in Chancroid
Johnson And Johnson · 1 drug in Chancroid
Pfizer · 1 drug in Chancroid
Pfizer Inc. · 1 drug in Chancroid
Poitiers University Hospital · 1 drug in Chancroid

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chancroid:

Cite this brief

Drug Landscape (2026). Chancroid — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chancroid. Accessed 2026-06-10.

Chancroid full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing